Calorie Restriction for Health & Longevity - Quick Reference Sheet

Calorie Restriction for Health & Longevity

Created on 09/20/2026 – Quick Reference based on Evidence Review created using AI4L / Opus 5 – Audit

Eating persistently less than the body would freely choose, with nutrient intake kept complete. Cholesterol, blood pressure, inflammation and insulin handling improve, even in people whose numbers already look healthy. Bone, muscle, hormones and energy expenditure pay the cost, and nearly every harm tracks how deep the deficit goes. Lifespan itself remains unmeasured in people. (Full Review)

Protocol

Deficit target
10–15% below maintenance
Practitioners set 10–25% below measured maintenance; 10–15% is what most sustain.
Establishing maintenance
Measured total daily energy expenditure
Not a predictive equation: self-reported intake under-reports and corrupts the calculation.
Nutrient adequacy first
Complete micronutrient intake at reduced energy
Nutrient density per calorie rises as calories fall, usually with a multivitamin as backstop.
Time to effect
Risk markers
4–12 weeks
Blood pressure, triglycerides and fasting insulin move first.
Bone and lean mass
12 months
Bone-resorption markers rise at 12 months; fat-free mass falls across two years.
Biological-aging signals
2 years
Pace-of-aging clock slowing appeared only over a full two-year trial.

Benefits

Contraindications
  • BMI below 18.5 kg/m², or unintentional loss above 5% of body weight in six months
  • Pregnancy, attempted conception, and lactation
  • Eating disorder active within five years
  • Age under 21, or continuing skeletal growth
  • Osteoporosis (T-score −2.5 or below) or prior fragility fracture
  • Frailty (Fried score 3 or more) or sarcopenia (appendicular lean mass index below 7.0 kg/m² men, 5.5 women)
  • Type 1 diabetes without specialist supervision; type 2 on insulin or secretagogues without a dose-reduction plan
  • Chronic kidney disease stage 4–5 (eGFR below 30)
  • Active infection or malignancy; perioperative period (four weeks either side)
  • Untreated hyperthyroidism, adrenal insufficiency, decompensated cirrhosis (Child-Pugh C)
  • SGLT2 inhibitors (empagliflozin, dapagliflozin, canagliflozin) during deep restriction
  • Bariatric surgery
Key Interactions
  • Insulin and secretagogues (glimepiride, gliclazide, glipizide, repaglinide)
  • Antihypertensives (lisinopril, amlodipine, hydrochlorothiazide)
  • Lithium
  • Levothyroxine
  • Warfarin
  • GLP-1 receptor agonists (semaglutide, tirzepatide, liraglutide)
  • Over-the-counter NSAIDs (ibuprofen, naproxen, aspirin)
  • Orlistat and stimulant appetite suppressants (caffeine, synephrine)
  • Glucose-lowering supplements (berberine, chromium, cinnamon, alpha-lipoic acid)
  • Blood-pressure-lowering supplements (beetroot nitrate, garlic, magnesium, potassium)
  • High-dose green tea catechin extract
  • Endurance training

Risk & Side Effects

  • High: Bone mineral density loss; loss of lean and skeletal muscle mass; persistent metabolic adaptation; poor long-term adherence and weight regain
  • Medium: Symptomatic gallstones with rapid or severe restriction; suppression of reproductive and sex hormones; anaemia and micronutrient shortfall
  • Low: Cold intolerance, fatigue and reduced spontaneous activity; preoccupation with food and disordered eating
  • Speculative: Impaired wound healing and host defence

Monitoring

Marker Target Why
Body weight and waist circumference 0.5–1.0% body weight per week; waist below 94 cm (men) / 80 cm (women) Confirms the deficit is the intended size
Fat mass and appendicular lean mass (DXA) Fat falling; appendicular lean mass index above 7.0 (men) / 5.5 kg/m² (women) Separates fat loss from lean loss
Bone mineral density (DXA, spine and hip) T-score above −1.0; no fall beyond scanner precision Detects the best-documented harm before fracture
Fasting insulin 2–5 µIU/mL Most responsive marker of the metabolic benefit
HOMA-IR Below 1.5 Single index of insulin resistance
HbA1c 4.8–5.4% Glycaemic benefit over 3 months, not one morning
ApoB Below 80 mg/dL (below 60 mg/dL if risk is elevated) Counts atherogenic particles directly
Triglycerides 50–80 mg/dL Among the fastest-moving lipid responses to a deficit
hs-CRP Below 0.5 mg/L Inflammation falls only with sustained restriction
TSH and free T3 TSH 0.5–2.0 mIU/L; free T3 upper half of range Falling free T3 signals too deep a deficit
Total testosterone (men) 500–900 ng/dL Detects reproductive-axis suppression
Oestradiol and cycle regularity (women) Cycles of 24–35 days; oestradiol appropriate to cycle phase Earliest reproductive sign; drives bone loss
Haemoglobin and ferritin Haemoglobin 13.5–15.5 (men) / 12.0–14.5 g/dL (women); ferritin 50–150 ng/mL Anaemia was flagged for monitoring by trial safety data
25-hydroxyvitamin D 40–60 ng/mL Supports calcium handling that offsets bone loss
Resting metabolic rate Within 10% of prediction for current lean mass Quantifies otherwise invisible metabolic adaptation
eGFR Above 90 mL/min/1.73 m² Guards against kidney strain at very low intake

Cadence: Baseline panel; weight and waist weekly; blood pressure weekly for six weeks on antihypertensives; bloods at 3 and 6 months, then every 6–12 months; DXA at 12 months, then every 12–24 months.

Qualitative Assessment

  • Cold intolerance — a new need for extra layers
  • Energy through the day, and whether afternoon fatigue is new
  • Training performance — strength, session quality, recovery
  • Libido and, in women, cycle regularity
  • Mood, irritability and tension
  • Sleep quality and night waking from hunger
  • Cognitive clarity and preoccupation with food
  • Hunger between meals, stable or escalating